Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02467387 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
A Phase 2 study of Non-Ischemic Heart Failure, sponsored by CardioCell.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 5
- Study locations
NCT02467387: Completed Phase 2 study of Non-Ischemic Heart Failure, sponsored by CardioCell.
NCT02467387 is a Phase 2 study of Non-Ischemic Heart Failure that has completed, run by CardioCell. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02467387, a Phase 2 study of Non-Ischemic Heart Failure, has completed, sponsored by CardioCell.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 5
- Study locations
Study Summary
A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.
Primary Outcome
As identified in the SAP, the safety analysis was the primary objective and was evaluated by the number of AEs
Conditions Studied
Interventions
- DRUG Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
- DRUG Lactated Ringer's Solution
Study Locations (5)
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Georgia
- Emory University Hospital - Atlanta
Illinois
- Northwestern University Centers for Heart Failure Therapy - Chicago
New York
- Stony Brook Heart Institute - Stony Brook
Pennsylvania
- Hospital of the University of Pennsylvania, Heart Failure and Transplant Program - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-06-01 |
| Est. Completion | 2017-05-11 |
| Phase | Phase 2 |
What the finished NCT02467387 record still lists
NCT02467387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Non-Ischemic Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) is the first listed.
NCT02467387 lists 5 locations in 5 states (District of Columbia, Georgia, Illinois).
Frequently Asked Questions
What is clinical trial NCT02467387 about?
NCT02467387 is a clinical study titled "A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure". A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.
What is the current status of trial NCT02467387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2014-06-01. Estimated completion is 2017-05-11.
What conditions does trial NCT02467387 study?
This clinical trial studies the following conditions: Non-Ischemic Heart Failure.
What interventions are being tested in trial NCT02467387?
The interventions under investigation include: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) (DRUG), Lactated Ringer's Solution (DRUG).
Who is sponsoring clinical trial NCT02467387?
This trial is sponsored by CardioCell, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02467387 being conducted?
This trial has 5 study locations across District of Columbia, Georgia, Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02467387's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI